AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...

AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve ...

Datopotamab deruxtecan is a TROP2-directed DXd ADC engineered by Daiichi Sankyo and co-developed by AstraZeneca and Daiichi Sankyo. The data pertaining to this compound will be presented at an ...

A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ambitions to hit an $80bn revenue target by 2030. Datopotamab deruxtecan ...

The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for ...

The Food and Drug Administration announced Friday it had broadened the approval of the FluMist nasal spray to become the ...

Arab Finance: AstraZeneca Egypt is planning to inject $50 million into new investments in Egypt, equivalent to nearly 50% of the company’s capital, the firm’s Country President Hatem Werdany stated.

The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's influenza nasal spray vaccine for ...

FluMist is a nasal spray manufactured by AstraZeneca that has been used to protect against influenza in the United States ...

FluMist is the first vaccine to prevent influenza that does not need to be administered by a healthcare provider, the ...

The Phase III trial compared the efficacy of Fasenra with the standard treatment of GSK’s Nucala in patients with ...

AstraZeneca has just scored big on the quest to make routine vaccinations less of a hassle. | The FDA signed off on ...